drugset / Trial / NCT00575874
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-06
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pioglitazone | Small molecule | 30 mg | — |
| Subject | Rivoglitazone | Small molecule | 0.5 mg | — |
| Subject | Rivoglitazone | Small molecule | 1 mg | — |
| Subject | Rivoglitazone | Small molecule | 1.5 mg | — |